Loading company…
Mainstay Medical develops ReActiv8, an implantable neurostimulation system for chronic mechanical low back pain.
Founded in 2008 and based in Dublin, Ireland, Mainstay Medical develops ReActiv8, an implantable neurostimulation therapy for disabling chronic mechanical low back pain. The US FDA approved ReActiv8 in June 2020. The company completed a dual listing on Euronext Paris and the Irish Stock Exchange in May 2014, and received EUR 108 million in equity financing in January 2021 and EUR 130 million in venture funding in September 2021. It plans to launch ReActiv8 in the US and continue expansion in Europe and Australia.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Mainstay Medical Holdings Plc? This is my company